PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
50 hedge funds and large institutions have $60M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 12 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 60 → 50 (-10)
29% less capital invested
Capital invested by funds: $84.3M → $60M (-$24.3M)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$682K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$622K |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$267K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$237K |
| 5 |
BlackRock
New York
|
+$213K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.77M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.46M |
| 3 |
Renaissance Technologies
New York
|
-$605K |
| 4 |
Millennium Management
New York
|
-$525K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$406K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Renaissance Technologies
New York
| – | -$605K | -131,500 | Closed |
|
|
52
Ameriprise
Minneapolis,
Minnesota
| – | -$406K | -88,346 | Closed |
|
|
BBP
53
Banco BTG Pactual
Rio De Janeiro,
Brazil
| – | -$154K | -33,500 | Closed |
|
54
TD Asset Management
Toronto,
Ontario, Canada
| – | -$149K | -32,443 | Closed |
|
|
SAMH
55
Shanda Asset Management Holdings
Tortola,,
British Virgin Islands
| – | -$140K | -30,500 | Closed |
|
56
First Trust Advisors
Wheaton,
Illinois
| – | -$138K | -30,008 | Closed |
|
|
PPA
57
Parametric Portfolio Associates
Seattle,
Washington
| – | -$92K | -20,066 | Closed |
|
|
FC
58
FORA Capital
Miami,
Florida
| – | -$58K | -12,556 | Closed |
|
59
RhumbLine Advisers
Boston,
Massachusetts
| – | -$55K | -11,932 | Closed |
|
60
UBS Group
Zurich,
Switzerland
| – | -$37K | -8,121 | Closed |
|
61
Simplex Trading
Chicago,
Illinois
| – | -$13K | -2,839 | Closed |
|
PHAS Hedge Fund Activity: Q3 2020 in Review
50 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q3 2020, worth a combined $60M — down 29% from $84.3M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PHAS and 3 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 18 added.
The largest buyer was Rock Springs Capital Management, adding an estimated $682K. The largest seller was Wellington Management Group, cutting an estimated $2.77M.
- 50 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q3 2020, down from 60 in Q2 2020.
- Funds reported $60M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q3 2020, down 29% quarter-over-quarter.
- 3 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 12 closed out, a net change of -9 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q3 2020 was Rock Springs Capital Management, an estimated $682K added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q3 2020 was Wellington Management Group, an estimated $2.77M sold.
Based on aggregated 13F filings for Q3 2020.